Creative Biolabs is an expert in the field of in vitro diagnostic (IVD) immunoassay development. We offer a comprehensive portfolio of services encompassing IVD antibody development, antibody pair development, immunoassay development, and IVD kit development. We target a wide range of biomarkers of different diseases, including isocitrate dehydrogenase [NAD] subunit alpha, mitochondrial (IDH3α).
IDH3α is an enzyme that in humans is encoded by the IDH3α gene located on the chromosome of 15q25.1. It belongs to the isocitrate dehydrogenases (IDHs) family, which comprises three isozymes: IDH1, IDH2, and IDH3. IDH3 is a heterotetramer composed of two 37-kDa α subunits (IDH3α), one 39-kDa β subunit (IDH3β), and one 39-kDa γ subunit (IDH3γ). As a member of the IDH family, IDH3 catalyzes the reversible oxidative decarboxylation of isocitrate to yield α-ketoglutarate (α-KG) and CO2 as part of the citric acid (TCA) cycle in glucose metabolism. IDH3 is responsible to catalyze the third step of TCA while converting NAD+ to NADH in the mitochondria within cells. It is primarily regulated by substrate availability, as well as positive and negative allosteric effectors. Calcium, citrate, and ADP can activate IDH3 whereas NADH, NADPH, and ATP inhibit its activity.
Fig.1 The subcellular localization of the three IDH isoforms and their roles in normal cellular metabolism. (Al-Khallaf, 2017)
IDH3α expression is implicated in cancer and shows a high basal expression in multiple cancer cell lines. IDH3α expression is associated with the poor postoperative overall survival of lung and breast cancer patients. Aberrant expression of IDH3α decreased α-ketoglutarate levels and increased the stability and transactivation activity of hypoxia-inducible factor 1 α (HIF-1α) in cancer cells. Meanwhile, the silencing of IDH3α significantly prevented tumor growth by suppressing the HIF-1-mediated Warburg effect and angiogenesis. These evidences showed that IDH3α could be explored as a novel target for the diagnosis and treatment of cancers. Besides, IDH3α has been reported to influence psychiatric disorders. Abnormal IDH3α levels in the cerebellum are significantly lower for major depressive disorder, bipolar disorder, and schizophrenia.
With over a decade of experience and expertise, Creative Biolabs is respected as a center of excellence in antibody and immunoassay development for both research and clinical applications. We offer biomarker-specific antibody development, characterization, engineering, and conjugation services. For immunoassay development, we offer services ranging from feasibility analysis, assay design, and assay protocol establishment to assay optimization and kit production. For more information, please click the following links:
Please feel free to contact us for more information and discuss your project needs.
References
For Research Use Only.
